Introduction {#sec1_1}
============

The use of potentially inappropriate medications (PIM) is a major issue in pharmaceutical therapy for older people because it can increase the risk of adverse drug events \[[@B1],[@B2],[@B3]\]. Older disabled adults, who often have complex comorbidities that require the prescription of multiple medications, may be highly susceptible to PIM use \[[@B4]\]. Previous studies \[[@B4],[@B5],[@B6],[@B7],[@B8],[@B9]\] on the use of PIM have predominantly focused on older populations receiving ambulatory visits or nursing home or home care, and the majority of these populations have a normal or mild-to-moderate functional dependence, but few studies \[[@B4],[@B10]\] have evaluated PIM use in older adults with a marked dependence in activities of daily living (ADL). Several criteria have been developed to identify PIM use in older populations \[[@B11],[@B12],[@B13],[@B14]\]. The Beers criteria, which were proposed by an expert panel using the Delphi method, were originally published in 1991 and were updated newly in 2012. They are the most widely applied criteria to measure geriatric use of PIM \[[@B11],[@B15]\]. A panel of European experts, also using the Delphi consensus method, recently developed a set of PIM-related criteria for elderly people, i.e. the Screening Tool of Older Persons\' potentially inappropriate Prescriptions (STOPP), which has been adopted by the European Union Geriatric Medicine Society \[[@B13]\]. Studies have increasingly used the STOPP criteria for the assessment of PIM in older people \[[@B7],[@B8],[@B9]\]. Therefore, the purpose of this study was to evaluate the frequency of prescription of PIM to older adults with marked dependence in ADL, using the STOPP and updated Beers criteria, and to compare the results obtained using each of the two sets of criteria.

Subjects and Methods {#sec1_2}
====================

Setting and Sample {#sec2_1}
------------------

This study was conducted at Chung Shan Medical University Hospital, a medical centre with \>1,300 beds in central Taiwan. Consecutive mobility-disabled patients aged ≥65 years requiring long-term specialized care (such as replacement of the Foley catheter, the nasogastric tube and the tracheal tube and chronic wound care) with and without other medical services in a community setting or at home, who were visited by health-care professionals and received long-term (≥28 days) prescriptions for chronic diseases between July 2012 and December 2012, were enrolled and their medical records were reviewed. Performance in ADL was measured using the Barthel index, with scores ranging from 0 to 100 and scores ≤60 indicating a marked ADL dependence \[[@B16]\]. This study evaluated 141 older mobility-disabled patients receiving the described services in the study hospital. The hospital\'s institutional review board approved this study, with qualification for a waiver of informed consent.

Data Collection and Measures {#sec2_2}
----------------------------

Data, including demographic information, medical history, comorbidities and current medications prescribed, were extracted from patients\' notes. The STOPP and Beers 2012 criteria were adopted to determine the use of PIM in the study patients \[[@B13],[@B15]\]. If a patient\'s condition was stable according to a physician\'s assessment, a long-term prescription was administrated by the NHI program \[[@B17]\]. If a patient had more than one visit for a refill prescription within the study period, only the first occurrence was used in analyses. The disease severity of each patient was assessed using the Charlson comorbidity index (CCI) \[[@B18]\]. Comorbidities were classified according to the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) \[[@B19]\].

Statistical Analysis {#sec2_3}
--------------------

All analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Cary, N.C., USA) and MedCalc Statistical Software version 13.2.2 (Broekstraat, Mariakerke, Belgium). Student\'s t tests were performed to compare continuous variables between groups. χ^2^, McNemar and Fisher exact tests were also applied to compare dichotomous variables between groups. The patients were divided into PIM (at least one PIM) and non-PIM (without any PIM) groups, and the risk factors for PIM were determined using logistic regression with purposeful selection of covariates. The methods of Hanley and McNeil \[[@B20]\] were used to analyse receiver-operating characteristic (ROC) curves and to estimate the areas under the ROC curves (AUC). The optimal cutoff number was calculated using the Youden index \[maximum (sensitivity + specificity − 1)\] \[[@B21]\]. Sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV) and likelihood ratios were then calculated according to the optimal cutoff value. OR and 95% CI were also estimated. A 2-tailed p \< 0.05 was considered statistically significant.

Results {#sec1_3}
=======

Of the 141 older adults with severe disability, 68 (48.2%) were men and 134 (95.0%) had complete ADL dependence (Barthel scale ≤20). The patients\' mean age was 81.5 ± 7.0 years (range 65--97) and their mean CCI score was 4.2 ± 2.1 (range 1--13). The mean number of medicines prescribed and coexisting disorders was 7.5 ± 3.4 and 7.7 ± 3.6, respectively. According to systemic disease categories, the patients\' most common comorbidities were cardiovascular disorders (n = 124; 87.9%) followed by neurological system disorders (n = 77; 54.6%). The prevalence of PIM identified using the STOPP and Beers 2012 criteria exhibited nonsignificant differences (94/141, 66.7% vs. 94/141, 66.7%). The PIM patients identified using the Beers criteria had a greater number of PIM incidents than those identified using the STOPP criteria (2.5 ± 1.8 vs. 2.0 ± 1.3; p =0.003). Of the PIM patients, 24 were identified by the STOPP criteria only, 24 were identified by the Beers criteria only and 70 were recognized by both sets of criteria. In the 24 patients identified using the STOPP criteria only, calcium channel blockers (CCB) were the most frequently prescribed PIM in 13 (54.2%) patients. However, in the 24 patients identified using the Beers criteria only, benzodiazepines or nonbenzodiazepine hypnotics were the most commonly prescribed PIM in 7 (29.2%) patients.

Based on the STOPP or Beers criteria, the PIM group had a greater number of drugs prescribed and coexisting disorders, and a higher frequency of psychiatric disorders, than the non-PIM group did (all p \< 0.05). According to the Beers criteria, the PIM group had a higher percentage (57/94, 60.6% vs. 20/47, 42.6%) of neurological disorders compared to the non-PIM group (p \< 0.05). However, according to the STOPP criteria, the percentages (54/94, 56.8% vs. 23/47, 50.0%) of neurological disorders in the two groups exhibited nonsignificant differences (p =0.339; table [1](#T1){ref-type="table"}). According to the STOPP criteria, CCB were the most frequently prescribed PIM (28 incidents in 26 patients). However, according to the Beers criteria, benzodiazepines or nonbenzodiazepine hypnotics (Z hypnotics) were the most commonly prescribed PIM (42 incidents in 27 patients).

In multivariate analysis, based on the Beers criteria, PIM use was associated with a high number of medicines prescribed (p = 0.013) and the presence of psychiatric disorders (p \< 0.001). On the other hand, according to the STOPP criteria, PIM use was only associated with a high number of medicines prescribed (p = 0.008; table [2](#T2){ref-type="table"}). The AUC for the number of medications prescribed for predicting the risk of PIM using the STOPP and Beers criteria were 0.644 and 0.673, respectively (both p \< 0.05). These values exhibited nonsignificant differences (p = 0.665; fig. [1](#F1){ref-type="fig"}). According to the Youden index, the optimal cutoff for the number of medications prescribed for predicting PIM using the STOPP or Beers criteria was 6. At a cutoff of ≥6 medications prescribed, the model based on the STOPP criteria had a sensitivity of 79%, a specificity of 38%, a PPV of 72% and an NPV of 47%, whereas the model based on the Beers criteria had a sensitivity of 81%, a specificity of 43%, a PPV of 74% and an NPV of 53%. The logistic regression analyses conducted to compare the risk of PIM in patients with \<6 drugs prescribed and in patients with ≥6 drugs prescribed, adjusting for baseline variables (age, sex and CCI) and other risk factors identified using the STOPP or Beers criteria, indicated that patients with ≥6 medications prescribed had a significantly higher risk of PIM, identified using the STOPP or Beers criteria, than patients with \<6 medications prescribed (STOPP criteria: adjusted OR = 2.1, 95% CI 1.1--5.0; Beers criteria: adjusted OR = 2.2, 95% CI 1.3--6.6; table [3](#T3){ref-type="table"}).

Discussion {#sec1_4}
==========

In this study, the major findings were as follows: (a) two thirds of the patients had been prescribed at least one PIM, irrespectively of screening using the STOPP or Beers 2012 criteria; (b) the prevalence of PIM use identified using the STOPP or Beers 2012 criteria exhibited nonsignificant differences, although the Beers 2012 criteria identified a greater number of PIM incidents in the PIM group compared to the STOPP criteria; (c) according to Beers 2012 criteria the use of PIM was associated with multiple drugs prescribed and the presence of psychiatric diseases, whereas according to the STOPP criteria PIM use was only associated with multiple drugs prescribed, and (d) CCB were the most commonly prescribed PIM identified using the STOPP criteria, whereas benzodiazepine or Z hypnotics were the most commonly prescribed PIM identified using the Beers 2012 criteria.

Our results on the prevalence of PIM in older disabled patients, as identified using the STOPP or Beers 2012 criteria, are higher than the prevalence rates reported in previous studies evaluating elderly people in nursing homes or receiving home care \[[@B1],[@B3],[@B4],[@B5]\]. The differences could have resulted from our patients having an almost complete ADL dependence and multiple complex comorbidities (mean CCI score \>4) and thus being weaker physically than the patients in previous reports \[[@B1],[@B3],[@B4],[@B5]\]. Our result that prescription of multiple drugs is a predictor of the risk of PIM is consistent with previous studies\' findings \[[@B1],[@B3],[@B4],[@B5],[@B8],[@B22]\]. However, no consensus exists on the minimum number of regular medications that need to be prescribed in order for the use to be considered polypharmacy (it has ranged from 4 to 20 drugs in previous studies) \[[@B1],[@B3],[@B4],[@B5],[@B9],[@B22],[@B23],[@B24]\]. Our data indicated that the number of medications prescribed was predictive of the risk of PIM in older disabled patients, irrespectively of identification using the STOPP or Beers 2012 criteria, and that an optimal cutoff (i.e. ≥6) for the number of drugs prescribed had a modest sensitivity and PPV in the prediction model. Whether the STOPP or Beers 2012 criteria were more sensitive at detecting PIM use in older patients with marked disability was unclear. ROC curve analyses indicated nonsignificant differences in the discriminative power of the two sets of criteria for predicting the risk of PIM, although the Beers 2012 criteria identified a greater number of PIM incidents than the STOPP criteria did. Several studies \[[@B1],[@B2],[@B3],[@B5],[@B6],[@B7],[@B8],[@B9],[@B10],[@B11],[@B12],[@B13]\] have revealed that explicit PIM criteria can be used as health-care quality indicators. However, the STOPP and Beers 2012 sets of criteria are complex (\>50 items in each set) and their application in clinical practice is time consuming \[[@B2],[@B11],[@B12],[@B13],[@B14],[@B15],[@B24]\]. It is thus essential to reduce the time required for applying the PIM criteria to increase the practicality of their usage. Electronic applications, such as computerized prescription safety alerts, pharmaceutical decision-making support software, and computerized advice or reminders for prescriptions, have reportedly reduced geriatric PIM in clinical practice \[[@B25],[@B26],[@B27],[@B28]\]. However, these real-time e-prescribing systems are costly and are not obtainable in medical settings with limited resources, particularly in developing countries \[[@B26],[@B27]\].

The high prevalence of benzodiazepine or Z hypnotic usage in patients with PIM identified using the Beers 2012 criteria, but not the STOPP criteria, could have been caused by the Beers 2012 criteria including the use of all benzodiazepines and Z hypnotics, whereas the STOPP criteria considered only the long-term use of long-acting benzodiazepines (or those with long-acting metabolites). However, benzodiazepines (all types) and Z hypnotics can increase the likelihood of cognitive deterioration, delirium, falls, fractures and even death in older people \[[@B4],[@B5],[@B11],[@B15],[@B29],[@B30],[@B31]\]. Hence, we suggest that benzodiazepines or Z hypnotics should be prescribed to older people with caution, and preferably only for short periods when no alternative medications are available. The PIM-related psychoactive drugs that were frequently prescribed to older patients with severe disability, identified using the Beers 2012 criteria, could explain the independent effect of psychiatric disorders on the risk of PIM, as reported previously \[[@B5],[@B23],[@B24]\]. Because the Beers 2012 criteria only listed nondihydropyridine CCB as PIM for older people with chronic constipation or systolic heart failure, CCB became less frequent PIM when using the Beers criteria compared to the STOPP criteria. Constipation could be actuated by dihydropyridine/nondihydropyridine CCB \[[@B15],[@B31]\]; therefore, physicians should consider prescribing medications other than CCB to older people with constipation.

The limitations of this study include its retrospective design and the use of data derived from a single medical center. Although all study patients\' prescriptions could be obtained through the Taiwanese NHI program and may minimize the use of over-the-counter drugs, data for over-the-counter medications were not obtained and might thus have underestimated the risk of PIM.

Conclusion {#sec1_5}
==========

Our data showed that prescription of multiple medications was associated with PIM use, as indicated by the STOPP or Beers 2012 criteria, in older disabled people. According to the Beers 2012 criteria, the presence of psychiatric disorders was also associated with PIM use. Our findings emphasize that physicians should be aware of the high risk of PIM in severely disabled older patients, particularly those taking ≥6 drugs.
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![ROC curves for the number of medications prescribed for predicting the risk of PIM according to the STOPP or Beers 2012 criteria. **a** When applying the STOPP criteria, the AUC was 0.644 (95% CI 0.559--0.723, p = 0.002. **b** When applying the Beers 2012 criteria, the AUC was 0.673 (95% CI 0.589--0.749, p \< 0.001). The diagonal reference line indicates no discrimination.](mpp-0024-0565-g01){#F1}

###### 

Baseline and clinical characteristics of 141 disabled older adults with and without PIM use, as identified using the STOPP and Beers 2012 criteria

  Variable                                                All patients (n = 141)   STOPP                                        Beers 2012                                                                                 
  ------------------------------------------------------- ------------------------ -------------------------------------------- -------------------------------------------- --------------------------------------------- ---------------------------------------------
  Instances of PIM per person, n                                                   1.8 ± 1.3[\*](#T1F2){ref-type="table-fn"}                                                 2.5 ± 1.8[\*](#T1F2){ref-type="table-fn"}     
  Age, years                                              81.5 ± 7.0               81.4 ± 7.3                                   81.7 ± 6.3                                   82.2 ± 7.1                                    80.1 ± 6.6
  Male gender                                             68 (48.2)                41 (43.6)                                    27 (57.4)                                    41 (43.6)                                     27 (57.4)
  CCI (points)                                            4.2 ± 2.1                4.4 ± 2.3                                    4.0 ± 1.9                                    4.4 ± 2.2                                     3.9 ± 2.0
  Barthel score ≤ 20                                      134 (95.0)               88 (93.6)                                    46 (97.9)                                    87 (92.6)                                     47 (100)
  Prescribed medications, n                               7.5 ± 3.4                8.1 ± 3.7[^+^](#T1F3){ref-type="table-fn"}   6.4 ± 2.2[^+^](#T1F3){ref-type="table-fn"}   8.1 ± 3.5[^\#^](#T1F4){ref-type="table-fn"}   6.4 ± 3.0[^\#^](#T1F4){ref-type="table-fn"}
  Coexisting disorders, n                                 7.7 ± 3.6                8.1 ± 3.8[^+^](#T1F3){ref-type="table-fn"}   6.8 ± 3.1[^+^](#T1F3){ref-type="table-fn"}   8.3 ± 3.7[^\#^](#T1F4){ref-type="table-fn"}   6.4 ± 3.0[^\#^](#T1F4){ref-type="table-fn"}
  Coexisting disorders[^a^](#T1F1){ref-type="table-fn"}                                                                                                                                                                    
   Cardiovascular                                         124 (87.9)               80 (85.1)                                    44 (93.6)                                    82 (87.2)                                     42 (89.4)
   Neurological                                           77 (54.6)                54 (56.8)                                    23 (50.0)                                    57 (60.6)[^\#^](#T1F4){ref-type="table-fn"}   20 (42.6)[^\#^](#T1F4){ref-type="table-fn"}
   Renal                                                  76 (53.9)                52 (55.3)                                    24 (51.1)                                    50 (53.2)                                     26 (55.3)
   Endocrinological                                       74 (52.5)                52 (55.3)                                    22 (46.8)                                    51 (54.3)                                     23 (48.9)
   Gastrointestinal                                       49 (34.8)                36 (38.3)                                    13 (27.7)                                    33 (35.1)                                     16 (34.0)
   Psychiatric                                            47 (33.3)                37 (39.4)[^+^](#T1F3){ref-type="table-fn"}   10 (21.3)[^+^](#T1F3){ref-type="table-fn"}   42 (44.7)[^\#^](#T1F4){ref-type="table-fn"}   5 (10.6)[^\#^](#T1F4){ref-type="table-fn"}
   Respiratory                                            46 (32.6)                31 (33.0)                                    15 (31.9)                                    27 (28.7)                                     19 (40.4)
   Musculoskeletal or connective tissue                   38 (27.0)                24 (25.5)                                    14 (29.8)                                    29 (30.9)                                     9 (19.1)
   Genitourinary                                          32 (22.7)                21 (22.3)                                    11 (23.4)                                    23 (24.5)                                     9 (19.1)
   Skin/subcutaneous                                      20 (14.2)                14 (14.9)                                    6 (12.8)                                     13 (13.8)                                     7 (14.9)
   Malignancies                                           10 (7.1)                 6 (6.4)                                      4 (8.5)                                      6 (6.4)                                       4 (8.5)

Values are presented as numbers (%) unless otherwise stated.

Patients included in more than one category were counted in each.

p \< 0.05 for comparing PIM incidents per person according to the two sets of criteria.

p \< 0.05 for comparing PIM and non-PIM groups according to the STOPP criteria.

p \< 0.05 for comparing PIM and non-PIM groups according to the Beers 2012 criteria.

###### 

Multivariate analysis of risk factors for PIM use identified using the STOPP or Beers 2012 criteria

  Variables                                     OR (95% CI)          p value
  --------------------------------------------- -------------------- ---------
  *According to STOPP criteria*                                      
  Number of medications prescribed              1.21 (1.05--1.38)    0.008
                                                                     
  *According to Beers 2012 criteria*                                 
  Number of medications prescribed              1.13 (1.03--1.25)    0.013
  Psychiatric diseases (presence vs. absence)   5.56 (2.68--11.56)   \<0.001

###### 

Sensitivity, specificity, predictive values, likelihood ratios, and OR for the optimal cutoff for the number of medications prescribed for predicting risk of PIM according to the STOPP and Beers 2012 criteria

  Cutoff ≥6 drugs[^a^](#T3F1){ref-type="table-fn"}   PIM group, n/total (%)   Non-PIM group, n/total (%)   Sen, % (95% CI)   Spe, % (95% CI)   PPV, % (95% CI)   NPV, % (95% CI)   PLR (95% CI)     NLR (95% CI)     Adjusted OR (95% CI)                               p
  -------------------------------------------------- ------------------------ ---------------------------- ----------------- ----------------- ----------------- ----------------- ---------------- ---------------- -------------------------------------------------- -------
  STOPP criteria                                     74/94 (78.7)             29/47 (61.7)                 79 (69--87)       38 (25--54)       72 (62--80)       47 (31--64)       1.3 (1.0--1.6)   0.6 (0.3--0.9)   2.1 (1.1--5.0) [^b^](#T3F2){ref-type="table-fn"}   0.034
                                                                                                                                                                                                                                                                        
  Beers 2012 criteria                                76/94 (80.9)             27/47 (57.4)                 81 (71--88)       43 (28--58)       74 (64--82)       53 (36--69)       1.4 (1.1--1.8)   0.5 (0.3--0.8)   2.2 (1.3--6.6)[^c^](#T3F3){ref-type="table-fn"}    0.012

NLR = Negative likelihood ratio; PLR = positive likelihood ratio; Sen = sensitivity; Spe = specificity.

Optimal cutoff value estimated using the Youden index.

Adjusted for age, sex and severity of comorbidities.

Adjusted for age, sex, severity of comorbidities and history of psychiatric disorders.
